Department of Biology, Metabolex Inc., 3876 Bay Center Place, Hayward, CA 94545, USA.
PPAR Res. 2007;2007:32696. doi: 10.1155/2007/32696.
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a key regulator of lipid metabolism and energy balance implicated in the development of insulin resistance and obesity. The identification of putative natural and synthetic ligands and activators of PPAR-gamma has helped to unravel the molecular basis of its function, including molecular details regarding ligand binding, conformational changes of the receptor, and cofactor binding, leading to the emergence of the concept of selective PPAR-gamma modulators (SPPARgammaMs). SPPARgammaMs bind in distinct manners to the ligand-binding pocket of PPAR-gamma, leading to alternative receptor conformations, differential cofactor recruitment/displacement, differential gene expression, and ultimately differential biological responses. Based on this concept, new and improved antidiabetic agents for the treatment of diabetes are in development. This review summarizes the current knowledge on the mechanism of action and biological effects of recently characterized SPPARgammaMs, including metaglidasen/halofenate, PA-082, and the angiotensin receptor antagonists, recently characterized as a new class of SPPARgammaMs.
过氧化物酶体增殖物激活受体γ(PPAR-γ)是脂质代谢和能量平衡的关键调节剂,与胰岛素抵抗和肥胖的发生有关。鉴定潜在的天然和合成的 PPAR-γ配体和激动剂有助于揭示其功能的分子基础,包括关于配体结合、受体构象变化和辅助因子结合的分子细节,从而产生了选择性 PPAR-γ调节剂(SPPARγMs)的概念。SPPARγMs 以不同的方式与 PPAR-γ的配体结合口袋结合,导致受体构象的改变,辅助因子的募集/置换的差异,基因表达的差异,最终导致生物学反应的差异。基于这一概念,正在开发新的和改进的抗糖尿病药物来治疗糖尿病。本综述总结了最近描述的 SPPARγMs 的作用机制和生物学效应的最新知识,包括 metaglidasen/halofenate、PA-082 和血管紧张素受体拮抗剂,最近被描述为一类新的 SPPARγMs。